摘要

Objectives: The objectives of this presentation is to review the current FDA pipeline that exists for new toxins that are making their way through the FDA process. Introduction: Botulinum toxin A transformed the aesthetic and cosmetic arena into heights that no one saw coming when the first toxin was approved many years ago. Conclusion: Newer toxins have emerged into the clinical scene and this presentation will differentiate these newer toxins and show the clinical evidence that has entered into the public domain with respect to these toxins. In addition, several newer toxins are in clinical trials at this time, and preliminary, public domain data will also be presented. It is an exciting time still for toxins for cosmetic use and we will focus on how some of these newer toxins may make a difference for our patients.